SL1 can function both as a molecular probe that binds with high affinity to cells overexpressing c-met in cell cultures and whole organisms and as a therapeutic antagonist for MM cells by inhibiting hepatocyte growth factor-induced c-met signaling. This evidence concerns the gene MET and Miyoshi myopathy.